JP2005528341A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528341A5
JP2005528341A5 JP2003567408A JP2003567408A JP2005528341A5 JP 2005528341 A5 JP2005528341 A5 JP 2005528341A5 JP 2003567408 A JP2003567408 A JP 2003567408A JP 2003567408 A JP2003567408 A JP 2003567408A JP 2005528341 A5 JP2005528341 A5 JP 2005528341A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
compound according
cycloalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003567408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528341A (ja
JP4439266B2 (ja
Filing date
Publication date
Priority claimed from GBGB0203412.2A external-priority patent/GB0203412D0/en
Application filed filed Critical
Publication of JP2005528341A publication Critical patent/JP2005528341A/ja
Publication of JP2005528341A5 publication Critical patent/JP2005528341A5/ja
Application granted granted Critical
Publication of JP4439266B2 publication Critical patent/JP4439266B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003567408A 2002-02-13 2003-02-11 2−オキサゾールアミンおよび5−ht2b受容体アンタゴニストとしてのその使用 Expired - Fee Related JP4439266B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203412.2A GB0203412D0 (en) 2002-02-13 2002-02-13 5-HT 2B receptor antagonists
PCT/GB2003/000552 WO2003068226A1 (en) 2002-02-13 2003-02-11 2-oxazolamines and their use as 5-ht2b receptor antagonists

Publications (3)

Publication Number Publication Date
JP2005528341A JP2005528341A (ja) 2005-09-22
JP2005528341A5 true JP2005528341A5 (enExample) 2006-02-09
JP4439266B2 JP4439266B2 (ja) 2010-03-24

Family

ID=9930999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003567408A Expired - Fee Related JP4439266B2 (ja) 2002-02-13 2003-02-11 2−オキサゾールアミンおよび5−ht2b受容体アンタゴニストとしてのその使用

Country Status (17)

Country Link
US (1) US7429607B2 (enExample)
EP (1) EP1474140B1 (enExample)
JP (1) JP4439266B2 (enExample)
KR (1) KR20040084905A (enExample)
CN (1) CN1633291A (enExample)
AU (1) AU2003207297B2 (enExample)
CA (1) CA2472762A1 (enExample)
DE (1) DE60317632T2 (enExample)
EA (1) EA200401077A1 (enExample)
GB (1) GB0203412D0 (enExample)
IL (1) IL163110A (enExample)
MX (1) MXPA04007738A (enExample)
NO (1) NO327465B1 (enExample)
NZ (1) NZ534539A (enExample)
PL (1) PL370221A1 (enExample)
WO (1) WO2003068226A1 (enExample)
ZA (1) ZA200406010B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299948B1 (it) 1998-04-02 2000-04-04 Azionaria Costruzioni Acma Spa Metodo e dispositivo per la formazione di gruppi di articoli appiattiti.
US20050176791A1 (en) * 2002-02-13 2005-08-11 Oxford Alexander W. 5-HT2B receptor antagonists
JP2006528617A (ja) * 2003-07-24 2006-12-21 ファーマジーン ラボラトリーズ リミテッド 5−ht2b受容体アンタゴニスト
WO2005079845A1 (ja) 2004-02-20 2005-09-01 Astellas Pharma Inc. 片頭痛予防薬
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005097113A2 (en) * 2004-04-08 2005-10-20 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
PL1797038T3 (pl) 2004-09-29 2012-11-30 Bayer Healthcare Llc Termodynamicznie trwała postać tosylanu bay 43-9006
WO2014085413A1 (en) * 2012-11-28 2014-06-05 Temple University - Of The Commonwealth System Of Higher Education Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2b activity modulators
KR101592068B1 (ko) 2013-11-08 2016-02-05 순천향대학교 산학협력단 플라즈마 아포리포프로테인 h를 포함하는 아스피린 과민성 호흡계 질환 및 아스피린 내성 천식 구별 진단용 마커 및 구별 진단용 키트
CN116789549A (zh) * 2023-06-16 2023-09-22 山东科源化工有限公司 一种羟基乙酸乙烯酯的制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658559A1 (de) * 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
WO1995024200A1 (en) 1994-03-11 1995-09-14 Eli Lilly And Company Method for treating 5ht2b receptor related conditions
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
ATE227710T1 (de) * 1996-04-03 2002-11-15 Takeda Chemical Industries Ltd Oxazole derivate,ihre herstellung und verwendung
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
EP1200093B1 (en) 1999-07-30 2003-09-24 Pharmagene Laboratories Ltd Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.

Similar Documents

Publication Publication Date Title
JP2010511721A5 (enExample)
JP2019104748A5 (enExample)
JP2006528617A5 (enExample)
JP2008510828A5 (enExample)
JP2005533804A5 (enExample)
JP2006515858A5 (enExample)
JP2020506951A5 (enExample)
JP2010504286A5 (enExample)
JP2011513410A5 (enExample)
JP2009536620A5 (enExample)
JP2005053931A5 (enExample)
JP2007534702A5 (enExample)
JP2013533228A5 (enExample)
JP2011522789A5 (enExample)
JP2005523310A5 (enExample)
JP2008500997A5 (enExample)
JP2012513416A5 (enExample)
JP2009538336A5 (enExample)
JP2009519243A5 (enExample)
JP2011227454A5 (enExample)
JP2019529419A5 (enExample)
JP2005530811A5 (enExample)
JP2005528341A5 (enExample)
JP2013515037A5 (enExample)
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b